CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Clovis Oncology, Inc.

5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States

Full Time Employees468

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. MahaffyCo-Founder, CEO, Pres & Exec. Director1.09MN/A1963
Dr. Gillian C. Ivers-ReadCo-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations647.05kN/A1954
Mr. Daniel W. MuehlExec. VP & CFO595.7kN/A1964
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPMExec. VP of Clinical, Preclinical Devel. & Pharmacovigilance and Chief Medical Officer702.04kN/A1968
Mr. Paul Edward GrossChief Compliance Officer, Exec. VP, Gen. Counsel & Sec.N/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Clovis Oncology, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.